Navigation Links
Senetek PLC Reports First Quarter 2008 Financial Results
Date:5/15/2008

biting them from selling any topical cosmetic non monograph products used for antiaging purpose and/or in connection with acne rosacea for a period of two years, along with rights to utilization of the "Triax Aesthetics" name in conjunction with the sales of existing packaged product inventory. The termination agreement is expected to be finalized shortly.

The Company will announce the date and time of a teleconference call for investors when the agreement to terminate its marketing agreement with Triax is finalized.

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-look
'/>"/>

SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Senetek PLC Announces Appointments of Key Personnel
2. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
3. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
4. China Biologic Products Reports First Quarter 2008 Results
5. Escalon(R) Reports Third Quarter Fiscal 2008 Results
6. Cadus Reports First Quarter 2008 Results
7. ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
8. SPO Medical Reports First Quarter 2008 Results
9. Nile Therapeutics Reports 2008 First Quarter Financial Results
10. Derma Sciences Reports First Quarter 2008 Results
11. NeurogesX Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Inverness Medical,Innovations, Inc. (Amex: IMA ) ... dated January 31, 2008 and entitled "Inverness Medical,Innovations ... and Medical Device Conference on February 5, 2008." ... Company,s presentation. The,correct time of the presentation is ...
... Calif., Feb. 1 Edwards Lifesciences,Corporation (NYSE: ... technologies to,treat advanced cardiovascular disease, is scheduled to ... Medical Device,Conference at the Grand Hyatt Hotel in ... M. Abate, Edwards Lifesciences, corporate vice president, chief,financial ...
... Inc.,(Nasdaq: VRUS ) management will be presenting at ... February 11 - 13, 2008 at the,Waldorf-Astoria Hotel in ... provide an overview of the company on Monday,February 11, ... Salon. In,addition, Dr. Michelle Berrey, Pharmasset,s Chief Medical Officer, ...
Cached Biology Technology:Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th 2
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... mobile commerce market, announces it has retained famous pickpocket, entertainer ... International CES debut of the Wocket™ biometric smart wallet.  ... NXT-ID booth January 6th and 7 th , 2015, demonstrating ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... MD FASEB MARC (Maximizing Access to Research Careers) ... Society for the Study of Reproduction (SSR) Annual Meeting ... These awards are meant to promote the entry of ... of the basic science community and to encourage the ...
... systems work together to paralyze skeletal muscles during rapid eye ... 11 issue of The Journal of Neuroscience . The ... including narcolepsy, tooth grinding, and REM sleep behavior disorder. ... recalled dreams occur your eyes continue to move but ...
... has been awarded a grant expected to total more ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... vaccine against HIV and the disease it causes, AIDS. ... vaccine is urgently needed to slow and eventually eliminate ...
Cached Biology News:Study identifies how muscles are paralyzed during sleep 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 3
... The BD FACSAria cell sorter sets a ... Based on a revolutionary new design ... high-speed sorting and multicolor analysis. The BD ... that incorporates a fixed-alignment cuvette flow cell. ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: